S&CO Inc. Has $925,000 Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

S&CO Inc. raised its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 49.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the biotechnology company’s stock after acquiring an additional 3,300 shares during the quarter. S&CO Inc.’s holdings in Blueprint Medicines were worth $925,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of BPMC. Allspring Global Investments Holdings LLC purchased a new position in Blueprint Medicines during the 1st quarter valued at about $218,000. Sei Investments Co. grew its stake in Blueprint Medicines by 36.6% during the 1st quarter. Sei Investments Co. now owns 45,913 shares of the biotechnology company’s stock valued at $4,355,000 after acquiring an additional 12,311 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Blueprint Medicines by 44.3% during the 1st quarter. Russell Investments Group Ltd. now owns 57,714 shares of the biotechnology company’s stock valued at $5,475,000 after acquiring an additional 17,712 shares in the last quarter. US Bancorp DE grew its stake in Blueprint Medicines by 5.2% during the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 183 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in Blueprint Medicines by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 15,218 shares of the biotechnology company’s stock valued at $1,444,000 after acquiring an additional 1,268 shares in the last quarter.

Blueprint Medicines Trading Down 7.3 %

NASDAQ BPMC opened at $88.69 on Friday. Blueprint Medicines Co. has a 12 month low of $62.56 and a 12 month high of $121.90. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The business’s 50-day moving average price is $89.59 and its two-hundred day moving average price is $98.91.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.20) EPS. Sell-side analysts expect that Blueprint Medicines Co. will post -3.61 earnings per share for the current year.

Insider Activity at Blueprint Medicines

In related news, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the transaction, the insider now directly owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This represents a 5.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.21% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BPMC has been the subject of several recent research reports. Robert W. Baird boosted their price target on Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Wedbush reiterated an “outperform” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Thursday. Baird R W upgraded Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Wells Fargo & Company decreased their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines has an average rating of “Moderate Buy” and a consensus target price of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.